Antiparkinson's Disease Drugs

Correct Answer

C — Catechol-O-methyltransferase inhibitor

Rationale

Opicapone is classified as a catechol-O-methyltransferase inhibitor — a drug class that blocks the enzyme responsible for metabolizing levodopa in peripheral tissues. It is a once-daily catechol-O-methyltransferase inhibitor used adjunctively with carbidopa-levodopa to reduce wearing-off. Monoamine oxidase B inhibitors such as selegiline and rasagiline slow dopamine breakdown inside the brain by a different enzyme. Dopamine agonists such as pramipexole and ropinirole directly stimulate dopamine receptors. Anticholinergic agents such as benztropine block muscarinic receptors in the striatum to reduce cholinergic excess.

Correct Answer

A — Ergot-derived dopamine agonist

Rationale

Bromocriptine is classified as an ergot-derived dopamine agonist. It belongs to the ergot alkaloid family of compounds and was the first dopamine agonist widely used in Parkinson's disease. Ergot-derived dopamine agonists are distinguished from non-ergot agents by their chemical scaffold, not their receptor mechanism — both subclasses stimulate dopamine receptors. Non-ergot dopamine agonists such as pramipexole, ropinirole, and rotigotine do not share the ergot chemical structure. Catechol-O-methyltransferase inhibitors and anticholinergic agents belong to entirely different drug classes with different pharmacological targets.

Correct Answer

B — Non-ergot dopamine agonist administered as a transdermal patch

Rationale

Rotigotine is classified as a non-ergot dopamine agonist delivered via a once-daily transdermal patch. Its non-ergot scaffold distinguishes it from bromocriptine and other ergot-derived agents, which carry a risk of fibrotic complications not seen with non-ergot agents. Its transdermal route provides continuous drug delivery that avoids first-pass metabolism and gastrointestinal adverse effects, making it useful when oral dosing is impractical. The subcutaneous injection route describes apomorphine, which is a separate non-ergot dopamine agonist used specifically for acute rescue during off episodes. No ergot-derived dopamine agonist is formulated as a transdermal patch.

Correct Answer

D — Subcutaneous dopamine agonist used as acute rescue therapy

Rationale

Apomorphine is classified as a subcutaneous dopamine agonist used as acute rescue therapy. It is administered by subcutaneous injection and has a rapid onset of action — within ten to twenty minutes — making it the only approved agent for acute rescue during sudden, severe off episodes in advanced Parkinson's disease. It is not an oral agent and is not used as initial monotherapy or routine adjunctive therapy. Bromocriptine is the ergot-derived dopamine agonist used historically as adjunctive therapy. Catechol-O-methyltransferase inhibitors such as opicapone and entacapone target levodopa metabolism, not dopamine receptors directly.

Correct Answer

A — Pramipexole and ropinirole

Rationale

Pramipexole and ropinirole are both classified as non-ergot dopamine agonists administered as oral tablets. Both are available in immediate-release and extended-release formulations and are the standard non-ergot oral dopamine agonists used for Parkinson's disease, either as initial monotherapy in younger patients or as adjunctive therapy with levodopa. Bromocriptine is ergot-derived, so it does not share the non-ergot classification with rotigotine. Apomorphine is a non-ergot agent but is administered subcutaneously, not orally, and is used for acute rescue rather than routine therapy. Entacapone and opicapone are catechol-O-methyltransferase inhibitors, a distinct drug class that targets levodopa metabolism rather than dopamine receptors.

Correct Answer

C — Antiemetic agent

Rationale

Trimethobenzamide is classified as an antiemetic agent — a drug used to prevent or treat nausea and vomiting. In the context of Parkinson's disease pharmacology, it is used as a required pretreatment before initiating apomorphine therapy, because apomorphine is a powerful emetogenic dopamine agonist that causes severe nausea in most patients without antiemetic cover. Trimethobenzamide is specifically chosen because it does not block dopamine receptors in the striatum, so it does not worsen motor symptoms. Dopamine agonists, monoamine oxidase B inhibitors, and catechol-O-methyltransferase inhibitors are all antiparkinson drug classes with entirely different pharmacological targets.

Correct Answer

B — Progressive loss of dopaminergic neurons eliminates the striatal buffering capacity that previously smoothed plasma levodopa fluctuations

Rationale

In early Parkinson's disease, enough dopaminergic neurons survive to take up levodopa-derived dopamine, store it, and release it slowly between doses — effectively buffering the sharp peaks and troughs of levodopa plasma levels and providing a continuous dopamine signal to the striatum. As neurodegeneration progresses and more neurons are lost, this storage and buffering capacity shrinks. Striatal dopamine then rises and falls in direct proportion to plasma levodopa concentration. When plasma levodopa drops toward the end of a dosing interval, striatal dopamine drops with it, and motor symptoms return. Wearing-off is therefore a pharmacokinetic consequence of progressive neurodegeneration, not a change in levodopa bioavailability, receptor sensitivity, or carbidopa efficacy. The levodopa molecule itself is unchanged — what changes is the brain's ability to handle intermittent delivery.

Correct Answer

D — Wearing-off is predictable and tied to the end of each dosing interval while on-off fluctuations are unpredictable and unrelated to dose timing

Rationale

Wearing-off — also called end-of-dose deterioration — occurs predictably as plasma levodopa levels fall toward the end of each dosing interval. Patients learn to anticipate it and recognize it as a return of stiffness, slowness, or tremor before their next scheduled dose. It resolves reliably with the next dose. On-off fluctuations are qualitatively different: motor control switches abruptly between functional on phases and severely impaired off phases without a predictable relationship to when the last dose was taken. The switches can occur within minutes and without warning. Both phenomena reflect progressive loss of dopamine buffering capacity, but on-off fluctuations additionally involve receptor-level changes in dopamine sensitivity that make the striatum respond erratically to any given plasma levodopa level. Dyskinesias are a separate complication — they occur during on phases at peak dopamine levels, not during off periods.

Correct Answer

A — Peak-dose dyskinesias caused by excessive striatal dopamine stimulation at maximum plasma levodopa concentration

Rationale

This patient's involuntary movements at peak levodopa plasma levels are peak-dose dyskinesias — the most common form of levodopa-induced dyskinesia. They occur when striatal dopamine stimulation is at its highest point in the dosing cycle, producing choreiform movements that are flowing and dance-like rather than the ratcheting tremor of the underlying disease. They represent the opposite problem from wearing-off: too much dopamine activity rather than too little. Many patients tolerate mild peak-dose dyskinesias and prefer them to the alternative of spending more time in an off state with reduced levodopa doses. Diphasic dyskinesias occur at the rising and falling phases of the levodopa curve — not at the peak — and tend to be more dystonic and violent. Wearing-off involves return of parkinsonian symptoms at trough levels, not involuntary movements. Freezing of gait is associated with off phases, not peak drug effect.

Correct Answer

C — Diphasic dyskinesias occurring at intermediate levodopa levels, indicating a severely narrowed therapeutic window

Rationale

This patient's pattern — dystonic involuntary movements at the rising and falling phases of the levodopa curve, absent at the peak — describes diphasic dyskinesias. They occur precisely when the plasma levodopa level is intermediate: neither at trough, where the patient is immobile with parkinsonian symptoms, nor at peak, where motor function is best. The therapeutic window has narrowed so severely that there is only a brief window of acceptable motor function at the true peak, flanked on both sides by dyskinesias at intermediate drug levels. Diphasic dyskinesias tend to be more dystonic and violent than the choreiform peak-dose type and are harder to manage because any dose adjustment either produces dyskinesias on one side or immobility on the other. Continuous drug delivery may be required to smooth these transitions.

Correct Answer

B — Amantadine

Rationale

Amantadine is the only drug with established efficacy specifically for levodopa-induced dyskinesias. Its antidyskinetic effect is mediated by N-methyl-D-aspartate receptor antagonism in the striatum — blocking glutamate receptors dampens the excessive glutamatergic excitability that contributes to the involuntary movements. This mechanism is distinct from amantadine's mild dopamine-releasing effect and operates independently of the dopaminergic system, which is why amantadine reduces dyskinesias without worsening motor control or requiring a levodopa dose reduction. Entacapone is a catechol-O-methyltransferase inhibitor that extends levodopa's plasma half-life and reduces wearing-off, but has no established antidyskinetic effect. Rasagiline is a monoamine oxidase B inhibitor used to reduce wearing-off by prolonging dopamine availability. Pramipexole is a dopamine agonist used as initial monotherapy or adjunctive therapy to smooth motor fluctuations.

Correct Answer

D — Converting pulsatile dopaminergic stimulation into more continuous receptor stimulation to reduce fluctuations

Rationale

All adjunctive strategies for motor complications in Parkinson's disease share the same underlying goal: smoothing the dopamine signal delivered to the striatum. Levodopa alone produces sharp peaks and troughs of dopamine stimulation because of its short half-life. These peaks drive dyskinesias and the troughs drive wearing-off. Monoamine oxidase B inhibitors extend the dopamine signal after each dose by slowing its breakdown. Catechol-O-methyltransferase inhibitors extend levodopa's plasma half-life by blocking peripheral metabolism. Dopamine agonists provide more sustained receptor stimulation because of their longer half-lives. Each strategy reduces the amplitude of the pulsatile pattern from a different pharmacological angle. Reducing total levodopa dose is a consequence of adding adjuncts rather than the goal the strategy is designed to achieve. Blocking cholinergic activity is the goal of anticholinergic drugs, a separate strategy. Increasing peak concentrations would worsen dyskinesias.

Correct Answer

A — Freezing of gait associated with off phases; poorly responsive to levodopa dose adjustment

Rationale

Freezing of gait is a sudden, transient inability to initiate or continue walking that is characteristic of advanced Parkinson's disease. It occurs most prominently during off phases — when dopamine levels are at their lowest — and is triggered by specific situations such as approaching doorways, turning, or navigating crowds. Despite occurring during off phases, freezing responds poorly to levodopa dose adjustments, in contrast to bradykinesia and rigidity which improve reliably with dopaminergic restoration. This poor levodopa responsiveness suggests that non-dopaminergic circuits contribute to freezing. It is a major cause of falls and injury. Peak-dose dyskinesias are involuntary movements that occur at maximum drug effect, not gait freezing at trough levels. Wearing-off involves a general return of parkinsonian features that resolves with the next dose — freezing has a different clinical character and different responsiveness to dose changes.

Correct Answer

C — They provide more sustained plasma levodopa levels, reducing the peak-to-trough fluctuations that cause end-of-dose motor deterioration

Rationale

Extended-release carbidopa-levodopa formulations release levodopa more slowly than immediate-release tablets, producing a flatter and more sustained plasma concentration curve. This reduces the sharp trough that develops at the end of each dosing interval with immediate-release formulations — the trough that causes wearing-off as striatal dopamine falls below the threshold needed for adequate motor control. By smoothing the levodopa concentration over a longer period, extended-release formulations extend the window of adequate motor control between doses. They do not produce higher peak concentrations — in fact, their peaks are generally lower and broader than immediate-release tablets. Their carbidopa content is standard, not enhanced. An important clinical caveat is that extended-release formulations have less predictable absorption than immediate-release tablets, which limits their utility in some patients and means their pharmacokinetic benefit comes with some variability in onset.

Correct Answer

D — Progressive loss of dopaminergic neurons has eliminated the striatal buffering capacity that previously smoothed plasma levodopa fluctuations, so motor control now tracks directly with plasma drug levels

Rationale

This patient's predictable, dose-timed deterioration is wearing-off — the most common motor complication of long-term levodopa therapy. In early disease, surviving dopaminergic neurons store dopamine derived from each levodopa dose and release it steadily between doses, smoothing the sharp fall in plasma levodopa that occurs as the drug's short half-life runs out. As Parkinson's disease progresses and more neurons are lost, this buffering capacity disappears. Striatal dopamine now rises and falls directly with plasma levodopa concentration. When plasma levodopa drops at the end of a dosing interval, motor symptoms return. The predictability of wearing-off — the same time before each dose, relieved by the next dose — is its defining clinical feature and distinguishes it from the unpredictable on-off fluctuations that emerge later. Wearing-off reflects the pharmacokinetic limitations of levodopa combined with progressive neuronal loss, not a change in receptor sensitivity or in carbidopa's efficacy.

Correct Answer

B — Peak-dose dyskinesias caused by excessive striatal dopamine stimulation at maximum plasma levodopa concentration

Rationale

This patient's choreiform involuntary movements occurring at peak drug effect — when motor control is otherwise best — are peak-dose dyskinesias. They develop after years of pulsatile levodopa stimulation and occur precisely when plasma levodopa concentration is at its highest, producing a transient state of excessive striatal dopamine activity. The movements are choreiform: flowing and dance-like rather than the ratcheting tremor of Parkinson's disease itself. Many patients remain unaware of mild peak-dose dyskinesias and prefer them to spending more time in the off state. The fact that these movements coincide with the period of best motor function and occur at a predictable time after each dose distinguishes them from diphasic dyskinesias, which occur at the rising and falling phases rather than the peak. Wearing-off involves return of parkinsonian symptoms at trough levels, not involuntary movements at peak effect.

Correct Answer

A — On-off fluctuations — unpredictable switches between functional and severely impaired motor states unrelated to dose timing

Rationale

This patient's sudden, unpredictable switches between mobile and immobile states with no clear relationship to dose timing are on-off fluctuations — a motor complication of advanced Parkinson's disease distinct from wearing-off. The hallmark of on-off fluctuations is their unpredictability: patients cannot reliably anticipate when an off phase will occur or what will trigger it, which makes planning daily activities impossible. The mechanism involves both the pharmacokinetic instability of levodopa and receptor-level changes in striatal dopamine sensitivity that develop after years of pulsatile stimulation. Wearing-off is predictable — it occurs at a consistent time before each dose and resolves reliably with the next one. Peak-dose dyskinesias are involuntary movements during on phases, not sudden switches to immobility. Diphasic dyskinesias are dystonic involuntary movements at intermediate drug levels, not abrupt transitions to severe parkinsonism.

Correct Answer

C — Blocking N-methyl-D-aspartate glutamate receptors in the striatum to dampen the excessive glutamatergic excitability that drives dyskinetic movements

Rationale

The drug added for this patient's peak-dose dyskinesias is amantadine — the only antiparkinson agent with established efficacy specifically for levodopa-induced dyskinesias. Its antidyskinetic effect is mediated by N-methyl-D-aspartate receptor antagonism in the striatum. Years of pulsatile dopaminergic stimulation produce changes in striatal circuitry that result in excessive glutamatergic activity, which contributes to the involuntary choreiform movements. By blocking N-methyl-D-aspartate receptors, amantadine dampens this glutamatergic hyperexcitability without requiring a reduction in levodopa dose — meaning the patient retains the motor benefit of her current levodopa regimen while the dyskinesias are reduced. Blocking dopamine D2 receptors would worsen the parkinsonian motor symptoms. Catechol-O-methyltransferase inhibitors extend levodopa half-life and reduce wearing-off, but have no established antidyskinetic effect. Monoamine oxidase B inhibitors prolong dopamine availability to reduce wearing-off, not to reduce dyskinesias.